Bevacizumab-related osteneocrosis of the jaw

International Journal of Immunopathology and Pharmacology

Volumn 22, Issue 4, 2009, Pages 1121-1123

  Serra, E ^b   Paolantonio, M ^a   Spoto, G ^a   Mastrangelo, F ^a   Tete S ^a   Dolci, Marco ^a  

^a UNIVERSITY OF CHIETI   (Italy)

^b NONE

Author keywords

Bevacizumab; Bone; Jaw; Osteonecrosis

Indexed keywords

AMOXICILLIN; BEVACIZUMAB; CLAVULANIC ACID; ZOLEDRONIC ACID;

ADULT; ALVEOLAR BONE; ANTIBIOTIC THERAPY; ARTICLE; BONE METASTASIS; CANCER RISK; CANCER SURGERY; CASE REPORT; DENTAL SURGERY; EXTRACTION; HUMAN; JAW OSTEONECROSIS; LUNG ADENOCARCINOMA; LUNG RESECTION; MALE; MICROCIRCULATION; PATIENT REFERRAL; PREOPERATIVE PERIOD; PRIORITY JOURNAL; TOOTH EXTRACTION;

EID: 76349114265     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463200902200429     Document Type: Article

References (12)

1. Woo S-B, Hellstein JW, Kalmar JR. Systematic review: Bisphopshonates and osteonecrosis of the jaw. Ann Intern Med 2006; 144:753-61.
2. Kerbel R, Folkman J. Clinical transaltion of angiogenesis inhibitors. Nat Rev Cancer 2002; 2:727-39.
3. Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: A critical cytokine in tumor angiogenesis and potential target for diagnosis and therapy. J Clin Oncol 2002; 20:4368-80.
4. Shih T, Lindley C. Bevacizumab. An angiogenesis inhibitor for the treatment of solid malignancies. Clin Ther 2006; 28:1779-802.
5. Estilo CL, Fornier M, Farooki A, Carlson D, Bohle G III, Huryn JM. Osteonecrosis of the jaw related to Bevacizumab. J Clin Oncol 2008; 26:4037-8.
6. C. Christodoulou, A. Pervena, G. Klouvas, et al. Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone. Oncology 2009; 76:209-11.
7. Ayllon J, Launay-Vacher V, Medioni J, Cros C, Spano JP, Oudard S. Osteonecrosis of the jaw under bisphosphonate and antiangiogenic Therapies: cumulative toxicity profile? Ann Oncol 2009 20: 600-1.
8. S. Greuter, F. Schmid, T. Ruhstaller, et al. Bevacizumab-associated osteonecrosis of the jaw Ann Oncol 2008 19:2091-2.
9. Fakih MG, Lombardo JC. Bevacizumab-induced nasal septum perforation. The Oncologist 2006; 11: 85-6.
10. Traina TA, Norton L, Drucker K, et al. Nasal septum perforation in a bevacizumab-treated patient with metastatic breast cancer. The Oncologist 2006; 11: 1070-1.
11. Aragon-Ching JB, Ning YM, Chen CC, et al. Higher incidence of osteonecrosis of the jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents. Cancer Invest 2009; 27:221-6.
12. Van Poznak C, Estilo C. Osteonecrosis of the jaw in cancer patiens receiving IV bisphosphonates. Oncology (Williston Park) 2006; 20:1053-62.